Markets
Jefferies analyst Brent Thill maintained a Buy rating on Microsoft (MSFT – Research Report) on April 21 and set a price target of $300.00. The company’s shares closed last Tuesday at $261.97, close to its 52-week high of $263.19.
According to TipRanks.com, Thill is a top 100 analyst with an average return of 28.3% and a 77.0% success rate. Thill covers the Technology sector, focusing on stocks such as SailPoint Technologies Holdings, Palantir Technologies, and CrowdStrike Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Microsoft with a $294.53 average price target, representing a 12.6% upside. In a report issued on April 8, Morgan Stanley also maintained a Buy rating on the stock with a $290.00 price target.
Ebro Foods (EBRPY) Gets a Buy Rating from Kepler Capital markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.
Markets
RBC Capital analyst Geoffrey Kwan maintained a Buy rating on CI Financial (CIFAF – Research Report) on April 23 and set a price target of C$24.00.
According to TipRanks.com, Kwan is a 3-star analyst with an average return of 3.3% and a 55.5% success rate. Kwan covers the Financial sector, focusing on stocks such as Brookfield Asset Mng, Element Financial, and Equitable Group.
Currently, the analyst consensus on CI Financial is a Moderate Buy with an average price target of $17.64.
Based on CI Financial’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $566 million and net profit of $105 million. In comparison, last year the company earned revenue of $536 million and had a net profit of $148 million.
Susquehanna Reiterates Their Hold Rating on ASML Holding (ASML) analystratings.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from analystratings.com Daily Mail and Mail on Sunday newspapers.
According to TipRanks.com, Gonsalves is ranked #356 out of 7474 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.42 average price target.
Based on Knight Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $55.19 million and net profit of $8.23 million. In comparison, last year the company earned revenue of $37.27 million and had a GAAP net loss of $6.67 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.